- Raised $2.6M, first half of $5M seed equity round led by Ferocity Capital
- Awarded DARPA SBIR ($1.8M) for production of materials for IND-enabling studies
- Selected as an awardee of the BLUE KNIGHT™ Resident QuickFire Challenge ($250K): Promoting Pivotal Progress
- Exclusive licensing agreement with Chrysea for biosynthetic hemoglobin production
- Selected to join BLUE KNIGHT™
- Featured in The New Yorker: The Long Quest for Artificial Blood
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Subcontract for DARPA FSHARP renewed for Year 3
- Team expanded to 12 employees
